Table 2.
Case reports of SGLT2 inhibitor-associated euDKA following ACS and PCI.
| Author | Age (years) | Sex | ACS type/PCI | SGLT2 inhibitor | Management of SGLT2 inhibitor | Onset of euDKA | Clue to diagnosis | Key diagnostic findings |
|---|---|---|---|---|---|---|---|---|
| Petersen C, et al. (2023) [5] | 28 | Male | NSTEMI/PCI | Empagliflozin | Initiated at discharge | Day 5 | Dyspnea, nausea, and vomiting | β-OHB: 9.0 mmol/dL pH 7.04 |
| Zughaib M, et al. (2023) [6] | 54 | Female | STEMI/PCI | Dapagliflozin | Continued use | Post-PCI | Nausea and vomiting | Ketonuria, ↑β-OHB (Values not reported) |
| Oriot P, et al. (2023) [7] | 77 | Female | STEMI/PCI | Empagliflozin | Continued use | Day 9 post-admission | Routine lab test (Asymptomatic) | β-OHB: 6.4 mmol/dL pH 7.22 |
| Yoshida Y, et al. (2025) [8] | 77 | Male | NSTEMI/PCI | Empagliflozin | Stopped on admission (1.5 days prior) | Post-PCI | Hemodynamic collapse | β-OHB: 4.3 mmol/dL pH 7.30 |
| Dai Z, et al. (2017) [9] | 49 | Male | STEMI/PCI | Ipragliflozin | Continued use (Stopped on diagnosis) | Acidosis present on arrival | Persistent unexplained acidosis | β-OHB: 6.8 mmol/dL pH 7.11 |
ACS, acute coronary syndrome; β-OHB, beta-hydroxybutyrate; euDKA, euglycemic diabetic ketoacidosis; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; SGLT2, sodium-glucose cotransporter 2.